Trinity Biotech PLC (TRIB)
Stock Price Chart
Key Info
| Market Cap | 56.85M |
| Revenue (ttm) | 90.44M |
| Net Income (ttm) | -28.91M |
| Shares Out | 20.90M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 30, 2020 |
| Last Price | $2.72 |
| Previous Close | $2.76 |
| Change ($) | -0.04 |
| Change (%) | -1.45% |
| Day's Open | 2.83 |
| Day's Range | 2.64 - 2.85 |
| Day's Volume | 115,911 |
| 52-Week Range | 0.56 - 3.28 |
More Stats
| Market Cap | 56.85M |
| Enterprise Value | 142.62M |
| Earnings Date (est) | Nov 17, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 20.90M |
| Float | n/a |
| EPS (basic) | -1.40 |
| EPS (diluted) | -1.30 |
| FCF / Share | -0.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 23,592 |
| Short Ratio | 0.18 |
| Short % of Float | n/a |
| Beta | 1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.63 |
| PB Ratio | 63.86 |
| Revenue | 90.44M |
| Operating Income | -24.11M |
| Net Income | -28.91M |
| Free Cash Flow | -5.98M |
| Net Cash | -85.77M |
| Net Cash / Share | -4.10 |
| Gross Margin | 45.87% |
| Operating Margin | -26.66% |
| Profit Margin | -32.00% |
| FCF Margin | -6.61% |
| ROA | -0.06% |
| ROE | -141.11% |
| ROIC | -16.20% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.44 | 97.04 | 99.14 | 99.61 | 100 | 105 | 91.22 | 82.51 | 77.95 | 89.64 |
| Revenue Growth | -6.8% | -2.12% | -0.47% | -0.58% | -4.46% | 14.97% | 10.55% | 5.85% | -13.04% | - |
| Gross Profit | 38.12 | 41.45 | 41.89 | 43.48 | 46.51 | 49.38 | 45.22 | 42.25 | 40.13 | 43.95 |
| Operating Income | -24.11 | -20.23 | -37.67 | -39.85 | 13.51 | 15.44 | 9.00 | 17.17 | 15.78 | 60.50 |
| Net Income | -28.91 | -22.09 | -40.27 | -101 | 21.80 | 17.21 | 9.65 | 17.34 | 15.59 | 60.42 |
| Shares Outstanding | 96.16 | 96.16 | 96.16 | 95.84 | 94.31 | 92.30 | 88.99 | 85.32 | 84.12 | 82.95 |
| Earnings Per Share | -1.40 | -1.04 | -1.88 | -4.40 | 0.48 | 0.72 | 0.40 | 0.76 | 0.72 | 2.80 |
| EPS Growth | - | - | - | - | -33.33% | 80% | -47.37% | 5.56% | -74.29% | - |
| Dividend Per Share | - | - | - | - | 0.22 | 0.22 | 0.20 | 0.15 | 0.10 | - |
| Dividend Growth | - | - | - | - | 0% | 10% | 33.33% | 50% | - | - |
| Operating Cash Flow | 5.88 | 5.98 | 9.37 | 10.56 | 13.52 | 15.69 | 8.77 | 18.82 | 18.77 | 22.97 |
| Capital Expenditures | -11.85 | -17.39 | -15.07 | -20.76 | -26.59 | -27.76 | -23.18 | -15.30 | -9.24 | -9.00 |
| Free Cash Flow | -5.98 | -11.41 | -5.70 | -10.21 | -13.07 | -12.07 | -14.41 | 3.53 | 9.54 | 13.97 |
| Cash & Equivalents | 16.40 | 30.28 | 57.61 | 77.11 | 102 | 9.10 | 22.32 | 74.95 | 71.09 | 58.00 |
| Total Debt | 102 | 82.34 | 93.84 | 93.24 | 92.83 | - | - | - | 0.11 | 0.27 |
| Net Cash / Debt | -85.77 | -52.07 | -36.23 | -16.13 | 9.13 | 9.10 | 22.32 | 74.95 | 70.98 | 57.73 |
| Assets | 131 | 152 | 193 | 250 | 364 | 243 | 226 | 197 | 171 | 161 |
| Liabilities | 126 | 108 | 128 | 141 | 150 | 45.87 | 43.48 | 28.03 | 20.17 | 19.59 |
| Book Value | 4.71 | 44.05 | 65.20 | 109 | 214 | 197 | 183 | 169 | 151 | 141 |
Company Profile
Company Details
| Full Name | Trinity Biotech PLC |
| Country | Ireland |
| Employees | 579 |
| CEO | Ronan O'Caoimh |
Stock Information
| Ticker Symbol | TRIB |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: TRIB |
Description
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.